Literature DB >> 12183272

Efficacies of quinupristin-dalfopristin combined with vancomycin in vitro and in experimental endocarditis due to methicillin-resistant Staphylococcus aureus in relation to cross-resistance to macrolides, lincosamides, and streptogramin B- type antibiotics.

Juliette Pavie1, Agnès Lefort, Virginie Zarrouk, Françoise Chau, Louis Garry, Roland Leclercq, Bruno Fantin.   

Abstract

A beneficial effect of the combination of quinupristin-dalfopristin and vancomycin was observed against two methicillin-resistant strains of Staphylococcus aureus harboring or not harboring the ermC gene, which codes for constitutive macrolide, lincosamide, and streptogramin B resistance. The beneficial effect was observed in time-kill studies, in which the drugs were used at inhibitory concentrations, and in a rabbit model of endocarditis, in which the combination was highly bactericidal and more active than monotherapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183272      PMCID: PMC127456          DOI: 10.1128/AAC.46.9.3061-3064.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500.

Authors:  S D Etienne; G Montay; A Le Liboux; A Frydman; J J Garaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.

Authors:  M C Ploy; C Grélaud; C Martin; L de Lumley; F Denis
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Ultrastructure alterations of Staphylococcus aureus exposed to RP59500.

Authors:  V Lorian; Y Esanu; L Amaral
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

5.  In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.

Authors:  S L Kang; M J Rybak
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

6.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

7.  In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.

Authors:  W Brumfitt; J M Hamilton-Miller; S Shah
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

8.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  J M Entenza; U Fluckiger; M P Glauser; P Moreillon
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

10.  Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.

Authors:  S L Kang; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  2 in total

1.  Antibiotic resistance and molecular characterization of clinical isolates of methicillin-resistant coagulase-negative staphylococci isolated from bacteremic patients in oncohematology.

Authors:  O Bouchami; W Achour; M A Mekni; J Rolo; A Ben Hassen
Journal:  Folia Microbiol (Praha)       Date:  2011-03-24       Impact factor: 2.099

2.  Community-associated methicillin-resistant Staphylococcus aureus: reconsideration of therapeutic options.

Authors:  Matthew E Levison; Shirley Fung
Journal:  Curr Infect Dis Rep       Date:  2006-01       Impact factor: 3.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.